1.
Circulation
; 128(24): 2622-703, 2013 Dec 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24226806
Assuntos
Trombose Coronária/prevenção & controle , Trombose Coronária/terapia , Cardiopatias/congênito , Cardiopatias/complicações , Adolescente , American Heart Association , Anticoagulantes/uso terapêutico , Criança , Pré-Escolar , Humanos , Lactente , Trombectomia , Terapia Trombolítica , Estados Unidos
2.
Pediatr Dermatol
; 26(5): 610-4, 2009.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19840322
RESUMO
Hemangioma of infancy is a condition that may be associated with significant morbidity. While evidence most supports the use of corticosteroids, there is no well-defined or Federal Drug Administration (FDA)-approved systemic therapy for hemangioma of infancy. All currently used treatments have significant risks. Dramatic improvement of complicated hemangioma of infancy to propranolol was recently reported, but details for initiating therapy, monitoring, and potential risks were not included. We present two infants treated with propranolol, who suffered complications and propose a treatment protocol to minimize potential adverse events.